Real-Life Evidence on Stroke Prevention in SPAF

Bayer8,607 enrolled

Overview

To obtain a better understanding on the comparative effectiveness of rivaroxaban and vitamin K antagonists (VKA) for stroke prevention in patients with non-valvular atrial fibrillation (SPAF) in a real-life setting

Study Type

OBSERVATIONAL

Enrollment

8,607

Conditions

Atrial Fibrillation (Prevention of Stroke)

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

As prescribed by treating physicians

Vitamin K antagonistsDRUG

As prescribed by treating physicians

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥18 years on the day of the first prescription of the study drug (= index date) during study selection window * Diagnosis of NVAF on start date of study or anytime during 365 days before this date * Availability of follow-up at least 180 days after the date of the first prescription of study drug within selection window of study (exposure start date) * Evidence of patient activity in the database during 90 days before the date of the first prescription of target drug within selection window. Exclusion Criteria: * Patients with valvular AF * Prescriptions of Oral Anticoagulants (OACs): VKA, Dabigatran, Rivaroxaban before index date * Prescription of more than one OAC on the index date or switch to another OAC during the follow-up period * Prescriptions of \< 15mg rivaroxaban at index date or during the follow-up period for patients in rivaroxaban cohort

Locations (1)

Unnamed facility

Many Locations, Germany

Outcomes

Primary Outcomes

Time to first occurrence of any of the following: Ischemic stroke (IS), Transient ischemic attack (TIA), Intracerebral hemorrhage (IH), Other non-traumatic intracranial hemorrhage including subdural hemorrhage, Myocardial infarction (MI)

Composite cardiovascular endpoint